Dystrogen Gene Therapiessp. z o.o.
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2019-08-14
Share capital
5,000.00 PLN
Registered address
ul. Władysława Pytlasińskiego 10/12/14, 00-777 Warszawa, Poland
Electronic delivery address
AE:PL-62810-66161-TEVDT-24
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2022 – the filing deadline has passed. 2 of 2 financial statements were filed late (the longest delay 794 days for 2020).
- 2022not filed
- 202118/12/2023
- 202018/12/2023
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2021.
Results vs industry
Revenue
This companyUSD 32.71kMedianUSD 55.24kAverageUSD 2.70m
Net profit
This companyUSD 2.04kMedianUSD -1.27kAverageUSD -92.18k
Operating costs
This companyUSD 25.25kMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 27.41kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Filip Jan Jeleń – President of the Management Board
Manner of representation
Each member of the management board is authorised to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Dystrogen Gene Therapies Inc. | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-10-07.
83 1090 1870 0000 0001 4308 0701
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 1, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Fundacja Innowacyjna Polska | |
| Apr 1, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | BTM Innovations sp. z o.o. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| AI Corelabsp. z o.o. | $106,857.00 | aicorelab.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| Orphinic ScientificS.A. | $42,972.42 | orphinic.com | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Immbionicsp. z o.o. | $31,756.23 | immbionic.com.pl | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Medtransfersp. z o.o. | $21,666.01 | codete.com | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl |
FAQ
The main business activity of Dystrogen Gene Therapies focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on August 14, 2019.
The headquarters is located at: ul. Władysława Pytlasińskiego 10/12, 00-777 Warszawa.
The management board consists of: Krzysztof Borys Siemionow (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2021 to December 31, 2021.
In 2021, the company generated total revenue of USD 32,710, representing a decrease of 76.3% compared to 2020.
Yes, the company recorded a net profit of USD 2,039 in 2021, meaning the company decreased its profit by 76.0%.
The largest operating cost category falls under other operating costs. This category amounted to USD 17,425 in 2021, representing 69% of all operating expenses.
Last updated: 2026-10-03